Title: EFFICACY OF USTEKINUMAB, VEDOLIZUMAB, OR A SECOND ANTI-TNF
AGENT AFTER THE FAILURE OF A FIRST ANTI-TNF AGENT IN PATIENTS WITH
CROHN’S DISEASE: A MULTICENTRE RETROSPECTIVE STUDY
Version: 4 Date: 05 Oct 2022
Reviewer's report:
- Cite “Onali S et al. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness
in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors. Am J Gastroenterol. 2022
Aug 1;117(8):1279-1287. doi: 10.14309/ajg.0000000000001773. Epub 2022 Apr 13. PMID:
35467558.”
“Manlay L, et al. Comparison of short- and long-term effectiveness between ustekinumab and
vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
Aliment Pharmacol Ther. 2021 Jun;53(12):1289-1299”
“Lenti MV, et al. A propensity score-matched, real-world comparison of ustekinumab vs
vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II. Aliment
Pharmacol Ther. 2021 Dec 22.”
- Report differences in the second anti-TNF response according to first anti-TNF primary or
secondary failure
- Use oxford comma in the whole text
- “Remission was defined as clinical remission with HBI < 4 without corticosteroid treatment
and was associated with the absence of an objective marker of inflammation (CRP < 5 mg/L or
faecal calprotectin < 250 µg/g or no endoscopic or radiological signs of activity).”
What about patients that stopped the biologic?
- Vedolizumab patients had more colonic (easier) location compared to ustekinumab and few
intestinal resection: add the history of intestinal resection in addition to location in multivariate
analysis
- Do not report in Figure 3 drug survival after week 100 because you have to few patients with
ustekinumab after this follow up
- “The higher drug survival of the combination therapy confirmed the recent study of the addition
of an immunosuppressant when switching anti-TNF agents in relapsing patients”
Is this true only for infliximab or also for adalimumab?
- “This study confirmed that the use of an anti-TNF agent remains the best choice in patients
with low trough levels rather than swapping the class”
Why not perform dose escalation?
- Since you found an inferior drug persistent for ustekinumab respect to vedolizumab, do you
conclude for a superiority of vedolizumab respect to ustekinumab in this setting?
Title: EFFICACY OF USTEKINUMAB, VEDOLIZUMAB, OR A SECOND ANTI-TNF
AGENT AFTER THE FAILURE OF A FIRST ANTI-TNF AGENT IN PATIENTS WITH
CROHN’S DISEASE: A MULTICENTRE RETROSPECTIVE STUDY
Version: 4 Date: 05 Oct 2022
Reviewer's report:
- Cite “Onali S et al. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness
in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors. Am J Gastroenterol. 2022
Aug 1;117(8):1279-1287. doi: 10.14309/ajg.0000000000001773. Epub 2022 Apr 13. PMID:
35467558.”
“Manlay L, et al. Comparison of short- and long-term effectiveness between ustekinumab and
vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
Aliment Pharmacol Ther. 2021 Jun;53(12):1289-1299”
“Lenti MV, et al. A propensity score-matched, real-world comparison of ustekinumab vs
vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II. Aliment
Pharmacol Ther. 2021 Dec 22.”
- Report differences in the second anti-TNF response according to first anti-TNF primary or
secondary failure
- Use oxford comma in the whole text
- “Remission was defined as clinical remission with HBI < 4 without corticosteroid treatment
and was associated with the absence of an objective marker of inflammation (CRP < 5 mg/L or
faecal calprotectin < 250 µg/g or no endoscopic or radiological signs of activity).”
What about patients that stopped the biologic?
- Vedolizumab patients had more colonic (easier) location compared to ustekinumab and few
intestinal resection: add the history of intestinal resection in addition to location in multivariate
analysis
- Do not report in Figure 3 drug survival after week 100 because you have to few patients with
ustekinumab after this follow up
- “The higher drug survival of the combination therapy confirmed the recent study of the addition
of an immunosuppressant when switching anti-TNF agents in relapsing patients”
Is this true only for infliximab or also for adalimumab?
- “This study confirmed that the use of an anti-TNF agent remains the best choice in patients
with low trough levels rather than swapping the class”
Why not perform dose escalation?
- Since you found an inferior drug persistent for ustekinumab respect to vedolizumab, do you
conclude for a superiority of vedolizumab respect to ustekinumab in this setting?
Please review this paper.
user
Title: EFFICACY OF USTEKINUMAB, VEDOLIZUMAB, OR A SECOND ANTI-TNF
AGENT AFTER THE FAILURE OF A FIRST ANTI-TNF AGENT IN PATIENTS WITH
CROHN’S DISEASE: A MULTICENTRE RETROSPECTIVE STUDY
Version: 4 Date: 05 Oct 2022
Reviewer's report:
- Cite “Onali S et al. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness
in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors. Am J Gastroenterol. 2022
Aug 1;117(8):1279-1287. doi: 10.14309/ajg.0000000000001773. Epub 2022 Apr 13. PMID:
35467558.”
“Manlay L, et al. Comparison of short- and long-term effectiveness between ustekinumab and
vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
Aliment Pharmacol Ther. 2021 Jun;53(12):1289-1299”
“Lenti MV, et al. A propensity score-matched, real-world comparison of ustekinumab vs
vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II. Aliment
Pharmacol Ther. 2021 Dec 22.”
- Report differences in the second anti-TNF response according to first anti-TNF primary or
secondary failure
- Use oxford comma in the whole text
- “Remission was defined as clinical remission with HBI < 4 without corticosteroid treatment
and was associated with the absence of an objective marker of inflammation (CRP < 5 mg/L or
faecal calprotectin < 250 µg/g or no endoscopic or radiological signs of activity).”
What about patients that stopped the biologic?
- Vedolizumab patients had more colonic (easier) location compared to ustekinumab and few
intestinal resection: add the history of intestinal resection in addition to location in multivariate
analysis
- Do not report in Figure 3 drug survival after week 100 because you have to few patients with
ustekinumab after this follow up
- “The higher drug survival of the combination therapy confirmed the recent study of the addition
of an immunosuppressant when switching anti-TNF agents in relapsing patients”
Is this true only for infliximab or also for adalimumab?
- “This study confirmed that the use of an anti-TNF agent remains the best choice in patients
with low trough levels rather than swapping the class”
Why not perform dose escalation?
- Since you found an inferior drug persistent for ustekinumab respect to vedolizumab, do you
conclude for a superiority of vedolizumab respect to ustekinumab in this setting?
assistant